Μύες & Απόδοση.
Εκκριτταγωγά αυξητικής ορμόνης και υλικό αυξητικών παραγόντων: ιπαμορελίνη, CJC-1295, GHRP-2 και GHRP-6, IGF-1 LR3, φολιστατίνη και σωματροπίνη. Η πιο συγκεχυμένη γωνιά της αγοράς — γι' αυτό κάθε σελίδα εδώ αναφέρει το ακριβές μόριο, με ή χωρίς DAC.
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%Πριν παραγγείλετε
PerformanceMyostatin inhibitors: ACE-083 went to phase 2, follistatin-344 never left the lab
One follistatin-based molecule grew muscle in two randomised phase 2 trials and still failed where it mattered. The other has only animal data, a black market, and a retinal case series. The published record, side by side.
PerformanceExercise mimetics: what AICAR, SLU-PP-332 and 5-Amino-1MQ have actually done, and in what species
One of these three has been given to 3,080 humans — and the trial was stopped for futility. The other two have never been given to a human at all. All three are sold on the same phrase, and the phrase comes from one mouse treadmill experiment in 2008.
GH axisIGF-1 LR3 and PEG MGF: two names, and what is actually published under each
Recombinant IGF-1 is an approved drug with a registry behind it. The LR3 analogue is a cell-culture reagent. PEG MGF has no administration study at all — the human MGF papers measure a gene switching on, not a peptide going in.